Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Collaborative Health Research Projects

University of Toronto

$122,500.00

Personalized Contingent Neurostimulation for Epilepsy by Machine Learning in Organic Brain Interfaces

EF 2022-23

Résumé
Epilepsy is a chronic, neurological condition characterized by unpredictable, disablingseizures. This devastating disorder increases mortality by 4 times and depression by 2 timespopulation rates. Unfortunately, epilepsy is extremely common, affecting 1 in 100 people, andin 33% of cases, medications do not prevent seizures. An emerging technology to aid suchpatients with drug-resistant epilepsy is contingent neurostimulation devices. These devicesare implanted in a patient so that they can detect epileptiform activity and electrically stimulatethe nervous system to prevent/abort seizures. Recently, two commercial contingentneurostimulators have been approved for treating epilepsy. These devices have provensuccessful at reducing seizure activity, however their efficacy is low. In particular, they arevery unlikely to produce seizure freedom, which is necessary to restore patient independenceand quality of life.The primary reasons why existing neurostimulation devices have had such limited successare that: (a) they use rudimentary (sparse and large) electrodes that poorly interface with thebrain and (b) they are extremely simplistic in their seizure detection and abortion capabilitiesdue to the use of basic electronics as constrained by energy limitations of an implant. Wepropose to combine (a) the far superior brain-interfacing electrode technology from ourpartner Panaxium and (b) our energy-efficient state-of-the-art implantable electronic circuitsthat employ artificial intelligence for optimal seizure prediction and prevention - to greatlyimprove the seizure-freedom efficacy of the neuromodulation therapy for intractable epilepsy.Our team is uniquely well qualified for this project. It is led by an expert in low-powerbiomedical and computational electronics (Genov), an epilepsy neurosurgeon and an expertin brain neurophysiology (Valiante), and Panaxiums Technology Commercialization Leaderand a 20-year industry veteran (Weinroth).
Programme
Collaborative Health Research Projects
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
549625-2020
Name nom
Genov, Roman R
Department département
Electrical & Computer Engineering, Edward S. Rogers Sr. Department of
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2022
Competition year année de concours
2020
Award amount
122500
Program id
CHRPJ
Program name en
Collaborative Health Research Projects
Program name fr
Projets de recherche concertée sur la santé
Group en
RESEARCH PARTNERSHIPS
Group fr
PARTENARIATS DE RECHERCHE
Committee code
360
Committee name en
Collaborative Health Research Projects Selection Panel
Committee name fr
Comité de sélection de projets de recherche concertée sur la santé
Area of application code
9999
Area of application group en
Not available
Area of application group fr
Non disponible
Area of application en
Not available
Area of application fr
Non disponible
Research subject code
2504
Research subject group en
Electrical and electronic engineering
Research subject group fr
Génie électrique et électronique
Research subject en
Integrated circuits
Research subject fr
Circuits intégrés
Installment
inst:4
Partie
1
Nb partie
4
Application title
Personalized Contingent Neurostimulation for Epilepsy by Machine Learning in Organic Brain Interfaces
Application summary
Epilepsy is a chronic, neurological condition characterized by unpredictable, disablingseizures. This devastating disorder increases mortality by 4 times and depression by 2 timespopulation rates. Unfortunately, epilepsy is extremely common, affecting 1 in 100 people, andin 33% of cases, medications do not prevent seizures. An emerging technology to aid suchpatients with drug-resistant epilepsy is contingent neurostimulation devices. These devicesare implanted in a patient so that they can detect epileptiform activity and electrically stimulatethe nervous system to prevent/abort seizures. Recently, two commercial contingentneurostimulators have been approved for treating epilepsy. These devices have provensuccessful at reducing seizure activity, however their efficacy is low. In particular, they arevery unlikely to produce seizure freedom, which is necessary to restore patient independenceand quality of life.The primary reasons why existing neurostimulation devices have had such limited successare that: (a) they use rudimentary (sparse and large) electrodes that poorly interface with thebrain and (b) they are extremely simplistic in their seizure detection and abortion capabilitiesdue to the use of basic electronics as constrained by energy limitations of an implant. Wepropose to combine (a) the far superior brain-interfacing electrode technology from ourpartner Panaxium and (b) our energy-efficient state-of-the-art implantable electronic circuitsthat employ artificial intelligence for optimal seizure prediction and prevention - to greatlyimprove the seizure-freedom efficacy of the neuromodulation therapy for intractable epilepsy.Our team is uniquely well qualified for this project. It is led by an expert in low-powerbiomedical and computational electronics (Genov), an epilepsy neurosurgeon and an expertin brain neurophysiology (Valiante), and Panaxiums Technology Commercialization Leaderand a 20-year industry veteran (Weinroth).